Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Table 1
Patient demographics.
Demographics
Kidney transplant patients
value
DES group ()
Non-DES group ()
Transplant date
1/4/07–4/18/15
1/10/07–4/17/15
Age, mean ± SD
49.6 ± 13.3
51.1 ± 14.2
0.11
Gender (female), (%)
226 (60.8)
157 (29.2)
<0.001
Race, (%)
0.27
African-American
69/368 (18.8)
84/499 (16.8)
Hispanic
101/368 (27.4)
167/499 (33.5)
White
148/368 (40.2)
180/499 (36.1)
Others
50/368 (13.6)
68/499 (13.6)
Living donor transplant, (%)
141 (37.9)
177 (32.9)
0.12
Induction, (%)
<0.001
Lymphocyte depletion
312/365 (85.5)
241/496 (48.6)
Anti-IL-2 receptor
53/365 (14.5)
255/496 (51.4)
Maintenance (tacrolimus), (%)
351/354 (99.2)
452/493 (91.7)
<0.001
HLA match, mean ± SD
1.9 ± 1.6
1.9 ± 1.7
0.78
PRA, (%)
<0.001
>10%
66 (17.7)
470 (87.3)
10–80%
113 (30.4)
68 (12.7)
>80%
193 (51.9)
0 (0)
Reason for DES, (%)
HS
314 (84.4)
na
HS/ABOi
17 (4.6)
na
ABOi
41 (11.0)
na
Recipient with CMV sero(−) at Tx, (%)
57/368 (15.5)
140/524 (26.7)
<0.001
Recipient with EBV sero(−) at Tx, (%)
13/361 (3.6)
33/486 (6.8)
0.04
Follow-up (months post-Tx), mean ± SD
24.4 ± 20.3
24.6 ± 20.1
0.84
Sample number tested for viral-PCR/patient, mean ± SD
9.7 ± 5.2
9.5 ± 7.4
0.61
HLA match in 350 DES and 392 non-DES patients with available results. Follow-up for viral-PCR monitoring. The number of patients with available results was provided if not available in all the patients. PRA: panel reactive antibody, DES: desensitization, HS: HLA-sensitization, ABOi: ABO incompatible transplantation, and Tx: transplant.
